GlassScriptPhysician profile
Charles P Rogers
NPI 1346350543
$9,024.56
in general payments reported to CMS, 2019-2025
53 companies · $1,360 in 2025
The $1,360 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $715 · 2020: $601 · 2021: $1,456 · 2022: $1,843 · 2023: $1,639 · 2024: $1,411 · 2025: $1,360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,409.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,148.97 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Astrazeneca Pharmaceuticals LP | $850.36 | 2019-2025 | Airsupra, Farxiga, Xigduo |
| Novo Nordisk INC | $795.70 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $736.89 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $735.47 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $705.03 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $636.17 | 2021-2025 | |
| Amgen INC. | $454.22 | 2019-2025 | Evenity, Prolia |
| Janssen Pharmaceuticals, INC | $402.22 | 2019-2025 | Invega Sustenna, Spravato, Xarelto |
| Otsuka America Pharmaceutical, INC. | $311.55 | 2022-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $190.49 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Sanofi-Aventis U.S. LLC | $189.22 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $170.95 | 2019-2024 | Xifaxan |
| Astellas Pharma US INC | $117.96 | 2022-2025 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $110.25 | 2021-2025 | Eliquis |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Rogers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.